A study by SEBI revealed that some listed Indian companies prioritized royalty payments to promoters over shareholder dividends. The study, conducted over a 10-year period, found that 25% of ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

Angel funds will conduct their first close by onboarding a minimum of five accredited investors, within 12 months from the date of SEBI communication for taking their private placement memorandum ...

Regulator Sebi on Wednesday proposed holding market infrastructure institutions and intermediaries accountable for any consequences arising from their use of artificial intelligence (AI ...

The Securities and Exchange Board of India (SEBI) is looking to broaden the scope of Unpublished Price Sensitive Information (UPSI) to improve transparency in market disclosures. The new ...

A recent study conducted by capital markets regulator Sebi revealed that listed companies ... In terms of royalty payments by net-loss-making companies, the study pointed out that there were ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

BHB-Phe, a newly discovered compound, reduces appetite and body weight by activating specific brain neurons. Researchers from ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...